Phenytoin Pharmacology
Phenytoin is an antiepileptic drug that stabilizes neuronal membranes through voltage-dependent blockade of sodium channels, preventing the spread of seizure activity while exhibiting saturable (non-linear) metabolism that creates a narrow therapeutic window requiring careful monitoring.
Mechanism of Action
Phenytoin works primarily at the motor cortex by blocking voltage-dependent sodium channels in a use- and frequency-dependent manner 1. This mechanism promotes sodium efflux from neurons and stabilizes the threshold against hyperexcitability 2. The drug selectively suppresses high-frequency neuronal firing (>10 Hz) while sparing normal brain activity at lower firing rates 1. This filtering effect prevents the positive feedback loop underlying maximal seizure activity without impairing normal neurological function 1.
The drug also reduces posttetanic potentiation at synapses, preventing cortical seizure foci from spreading to adjacent areas, and decreases maximal activity of brainstem centers responsible for tonic-clonic seizures 2.
Pharmacokinetics
Absorption and Distribution
- Bioavailability: Dependent on particle size and formulation 3
- Peak levels:
- Volume of distribution: Moderately large 3
- Protein binding: ~90% bound to plasma albumin 3
Metabolism - Critical Non-Linear Kinetics
Phenytoin exhibits saturable metabolism, creating non-linear pharmacokinetics that is clinically crucial 2, 3. The drug is hydroxylated in the liver primarily to 5-(p-hydroxyphenyl)-5-phenylhydantoin (HPPH) by CYP2C9 and CYP2C19 enzymes 4, 5. Because this enzyme system becomes saturated at therapeutic levels, small dose increases (≥10%) can produce disproportionately large increases in serum levels and potential toxicity 2.
Key metabolic pathways:
- Primary metabolism: CYP2C9 (major), CYP2C19 4, 5
- Secondary metabolism: CYP3A4, 3A5, 3A7 also contribute to HPPH oxidation 4
- Genetic variability: CYP2C9 polymorphisms significantly affect clearance 5
Elimination
- Half-life: Average 22 hours (range 7-42 hours) 2
- Time to steady state: 7-10 days (5-7 half-lives) 2
- Excretion: Primarily biliary as inactive metabolites, then reabsorbed and excreted renally 2
Therapeutic Drug Monitoring
Therapeutic range: 10-20 mcg/mL (some patients controlled at lower levels) 2
Timing of Levels
- Trough levels: Obtained just before next dose; assess compliance and therapeutic adequacy 2
- Peak levels: Obtained 4-12 hours post-dose for extended-release; identify threshold for toxicity 2
- When to check: At least 5-7 half-lives after initiation, dose change, or drug addition 2
Loading Strategies
Multiple effective approaches exist 6, 7:
Intravenous phenytoin:
- 18 mg/kg at maximum rate of 50 mg/min
- Achieves therapeutic levels within minutes after infusion 6, 7
- Major adverse effects: Hypotension, bradyarrhythmias, cardiac arrest, purple glove syndrome, tissue necrosis 6
- Contains propylene glycol (40%) and ethanol (10%) at pH 12 6
Intravenous fosphenytoin:
- 18 PE/kg at maximum rate of 150 PE/min
- Significantly safer profile with fewer local and systemic effects 6, 7
- More water-soluble, lacks propylene glycol/ethanol 6
- Higher acquisition cost but generic now available 7
Intramuscular fosphenytoin:
- Produces therapeutic levels within 1 hour 6
Oral loading:
- 20 mg/kg divided in maximum 400 mg doses every 2 hours 7
- Achieves therapeutic levels in 3-8 hours 6
- Cheaper but slower than IV 7
Oral maintenance without loading:
Adverse Effects
Dose-Related (Common to All Routes)
- Ataxia, nystagmus, tremor, somnolence 6
Serious Adverse Events
- Cardiovascular: Hypotension, dysrhythmias, cardiac arrest (primarily IV phenytoin) 6, 7
- Dermatologic: Stevens-Johnson syndrome, toxic epidermal necrolysis (associated with HLA-B*15:02) 5
- Local: Purple glove syndrome, phlebitis, tissue necrosis (IV phenytoin) 6
Special Populations
Renal Failure
- Reduced protein binding → lower total serum concentrations needed for therapeutic effect 3
- Free drug concentration remains appropriate despite lower total levels 3
Hepatic Disease
Pregnancy
- Serum concentrations may fall progressively due to increased metabolism 3
- Drug readily crosses placenta 3
- Neonates metabolize rapidly after in utero exposure 3
Drug Interactions
Phenytoin is highly prone to pharmacokinetic interactions 8:
Drugs Decreasing Phenytoin Metabolism (Increase Levels)
- Valproic acid, isoniazid, cimetidine, phenylbutazone, chloramphenicol, sulfonamides 8
Drugs Increasing Phenytoin Metabolism (Decrease Levels)
- Rifampicin, dexamethasone 8
Phenytoin as Enzyme Inducer
- Increases clearance of: carbamazepine, theophylline, methadone, corticosteroids, oral contraceptives, warfarin 8
Protein Binding Displacement
- Valproic acid, salicylates, phenylbutazone 8
- Alters total but not free concentrations, complicating interpretation 8
Food/Herb Interactions
- Folic acid: Can be co-administered to prevent deficiency without affecting efficacy 9
- Piperine: Requires monitoring due to increased absorption 9
- Noni: Should be avoided; may reduce levels to subtherapeutic range 9
Clinical Pearls
The saturable metabolism is the most critical pharmacokinetic feature - because the enzyme system operates near capacity at therapeutic doses, the relationship between dose and serum concentration is non-linear 2, 3. This means a 10% dose increase can produce a >10% increase in serum levels, potentially causing toxicity 2.
Monitoring is essential - wide interpatient variability exists even with equivalent dosing 2. Follow-up monitoring on an outpatient basis is important regardless of loading strategy 6.
Genetic testing may be valuable - CYP2C9 and HLA-B genotyping can guide dosing and identify patients at risk for severe cutaneous reactions 5.